Elevated IOP in Patients with Ocular Hypertension, Chronic Angle Closure Glaucoma, and Primary Open Angle Glaucoma
Ocular Hypertension and Glaucoma
MicroProstTM is our proprietary prostaglandin microdose formulation and candidate for the first-line treatment of ocular hypertension (OHT), chronic angle closure glaucoma (CACG), and primary open angle glaucoma (POAG). MicroProst’s MILAGRO Phase III study is expected to start at the end of 2019. If approved, this product will have the broadest indication of any once-daily glaucoma therapy currently available in the US.
Our microdosing technology may also address side effects such as loss of skin tone around the eyes and red eyes, help with poor drop instillation associated with traditional eyedropper bottles.
Learn more about our Milagro Study
We will begin our MILAGRO later in 2019. We believe the study will open a new treatment paradigm for glaucoma and ocular hypertension patients and provide eye care practitioners with a way to reduce drug and preservative exposure to sensitive tissues.